# Potential Protective Effect of Carotid Endarterectomy: Inducing Ischemic Tolerance in Brain Tissue after Stroke

**Authors:** Rastislav Mucha, Marek Furman, Alexandra Urbanova, Ivan Kopolovets, Miroslava Nemethova, Michal Virag, Stanislav Hresko, Vladimir Katuch, Vladimir Sihotsky

PMC · DOI: 10.1007/s12031-025-02470-0 · Journal of Molecular Neuroscience · 2026-02-03

## TL;DR

This study explores how carotid endarterectomy may protect the brain after stroke by inducing ischemic tolerance through changes in gene expression in blood.

## Contribution

The study identifies gene expression changes in peripheral blood during carotid endarterectomy that may reflect ischemic tolerance mechanisms.

## Key findings

- CEA induced gene expression changes in peripheral blood associated with ischemic tolerance.
- Differential gene expression was observed across symptomatic, asymptomatic, and oximetric patient groups.
- Monitored genes showed statistically significant differences, suggesting distinct ischemic tolerance cascades.

## Abstract

Stroke is a serious disease, ranking among the leading causes of mortality and permanent disability in EU countries. The ischemic cascade, triggered by the blockage of oxygenated blood supply to brain tissue, leads to excitotoxicity, oxidative stress, inflammation, and eventually, cell death. Current research highlights the promising neuroprotective effects of conditioning, which induces ischemic tolerance (IT). Thus, the main objective of this study is to analyze selected genes affected by ischemic stroke and the neuroprotective response to ischemic stroke, with a focus on ischemia and ischemic tolerance in peripheral blood. We investigated changes in gene expression indicative of cerebral ischemia during carotid endarterectomy (CEA), a procedure that involves the temporary occlusion of the arteria carotis interna. To assess the influence of CEA on IT induction, we performed a whole-transcriptome analysis of peripheral blood cells isolated from symptomatic (791 DEGs in correlation with negative control), asymptomatic (688 DEGs in correlation with negative control), and oximetric (637 DEGs in correlation with negative control) patients. The presence of gene expression changes in genes selectively identified through whole-transcriptome analysis was subsequently statistically verified. Using quantitative qRT-PCR, we monitored gene expression changes in10 genes SLC2A14, TRPM7, UGP2, PLLP, ND4L, HMSD, SESN3, DPY19L4, UBE3A, and PCDH9. The results suggest that CEA affected the expression of all monitored genes, with statistically significant differences between groups, indicating the activation of distinct ischemic tolerance cascades in different patient groups. These findings may contribute to a better understanding and characterizing of the molecular mechanisms underlying ischemic tolerance.

Whole transcriptome expression changes were identified in stroke

A potential method of neuroprotection activation after stroke was identified

Potential blood-based markers of stroke and neuroprotection were identified

## Linked entities

- **Genes:** SLC2A14 (solute carrier family 2 member 14) [NCBI Gene 144195], TRPM7 (transient receptor potential cation channel subfamily M member 7) [NCBI Gene 54822], UGP2 (UDP-glucose pyrophosphorylase 2) [NCBI Gene 7360], PLLP (plasmolipin) [NCBI Gene 51090], ND4L (NADH dehydrogenase subunit 4L) [NCBI Gene 4539], HMSD (histocompatibility minor serpin domain containing) [NCBI Gene 284293], SESN3 (sestrin 3) [NCBI Gene 143686], DPY19L4 (dpy-19 like 4) [NCBI Gene 286148], UBE3A (ubiquitin protein ligase E3A) [NCBI Gene 7337], PCDH9 (protocadherin 9) [NCBI Gene 5101]
- **Diseases:** stroke (MONDO:0005098)

## Full-text entities

- **Genes:** HMSD (histocompatibility minor serpin domain containing) [NCBI Gene 284293] {aka ACC-6, ACC6, C18orf53, HSMD-v}, SLC2A14 (solute carrier family 2 member 14) [NCBI Gene 144195] {aka GLUT14, SLC2A3P3}, ND4L (NADH dehydrogenase subunit 4L) [NCBI Gene 4539] {aka MTND4L}, UGP2 (UDP-glucose pyrophosphorylase 2) [NCBI Gene 7360] {aka DEE83, EIEE83, SVUGP2, UDPG, UDPGP, UDPGP2}, IRF1 (interferon regulatory factor 1) [NCBI Gene 3659] {aka IMD117, IRF-1, MAR}, SESN3 (sestrin 3) [NCBI Gene 143686] {aka SEST3}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CAMK2G (calcium/calmodulin dependent protein kinase II gamma) [NCBI Gene 818] {aka CAMK, CAMK-II, CAMKG, MRD59}, TRPM7 (transient receptor potential cation channel subfamily M member 7) [NCBI Gene 54822] {aka ALSPDC, CHAK, CHAK1, LTRPC7, LTrpC-7, TRP-PLIK}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, IRF4 (interferon regulatory factor 4) [NCBI Gene 3662] {aka IMD131, LSIRF, MUM1, NF-EM5, SHEP8}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, PLLP (plasmolipin) [NCBI Gene 51090] {aka PMLP, TM4SF11}, DPY19L4 (dpy-19 like 4) [NCBI Gene 286148], CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, PCDH9 (protocadherin 9) [NCBI Gene 5101], UBE3A (ubiquitin protein ligase E3A) [NCBI Gene 7337] {aka ANCR, AS, E6-AP, EPVE6AP, HPVE6A, PIX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** occlusion of the arteria carotis interna (MESH:D007762), injury (MESH:D014947), ischemia (MESH:D007511), Cardiovascular Diseases (MESH:D002318), deaths (MESH:D003643), hypoxia (MESH:D000860), brain oedema (MESH:D001929), restenosis (MESH:D023903), ischemic tolerance (MESH:D018149), atherosclerotic plaque (MESH:D058226), neurological disorders (MESH:D009461), MCA (MESH:D020244), atherosclerosis (MESH:D050197), neuronal apoptosis (MESH:D065703), acute and chronic kidney or liver diseases (MESH:D000208), inflammation (MESH:D007249), occlusion of (MESH:D001157), brain injury (MESH:D001930), ischemic heart disease (MESH:D017202), acute or chronic infections (MESH:D054198), IR injury (MESH:D015427), TIA (MESH:D002546), thrombosis (MESH:D013927), carotid artery occlusion (MESH:D002340), stenosis (MESH:D003251), neurodegeneration (MESH:D019636), IS (MESH:D002544), brain damage (MESH:D001925), Ischemic (MESH:D002545), autoimmune diseases (MESH:D001327), Stroke (MESH:D020521), CEA (MESH:D016893), brain tissue damage (MESH:D017695), neuropathic pain (MESH:D009437), conditions (MESH:D020763), hypoxic (MESH:D002534), seizures (MESH:D012640), embolic disease (MESH:D004617), coagulation disorders (MESH:D001778)
- **Chemicals:** ROS (MESH:D017382), ATP (MESH:D000255), clopidogrel (MESH:D000077144), dehydroascorbic acid (MESH:D003683), oxygen (MESH:D010100), chloroform (MESH:D002725), Phosphate (MESH:D010710), glycogen (MESH:D006003), NaCl (MESH:D012965), KCl (MESH:D011189), PBS (MESH:D007854), heparin (MESH:D006493), UDP-glucose (MESH:D014532), waixenicin A (MESH:C568854), lipid (MESH:D008055), calcium (MESH:D002118), TRIzol (MESH:C411644), deoxyglucose (MESH:D003847), glucose 6-phosphate (MESH:D019298), iron (MESH:D007501), isopropanol (MESH:D019840), Asym (-), glucose 1-phosphate (MESH:C031590)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Cercopithecidae (monkey, family) [taxon 9527], Homo sapiens (human, species) [taxon 9606], Macaca mulatta (rhesus macaque, species) [taxon 9544], Canis lupus familiaris (dog, subspecies) [taxon 9615]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12868017/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12868017/full.md

---
Source: https://tomesphere.com/paper/PMC12868017